Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Public ClinicalTrials.gov record NCT03428802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability
Study identification
- NCT ID
- NCT03428802
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Enrollment
- 21 participants
Conditions and interventions
Conditions
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Locally Advanced Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- POLD1 Gene Mutation
- POLE Gene Mutation
- Recurrent Malignant Solid Neoplasm
- Recurrent Ovarian Carcinoma
- Stage III Breast Cancer AJCC v7
- Stage III Ovarian Cancer AJCC v8
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIC Breast Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
Interventions
- Laboratory Biomarker Analysis Other
- Pembrolizumab Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2018
- Primary completion
- Nov 23, 2024
- Completion
- Sep 20, 2027
- Last update posted
- Apr 2, 2026
2018 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03428802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03428802 live on ClinicalTrials.gov.